Comment on “Hypothermic machine perfusion in liver transplantation—a randomized trial”
French Editorial from the ACHBPT

Comment on “Hypothermic machine perfusion in liver transplantation—a randomized trial

Fabien Robin1,2, Heithem Jeddou1

1Department of Hepatobiliary and Digestive Surgery, University Hospital, Rennes 1 University, Rennes, France; 2INSERM U1242, Chemistry Oncogenesis Stress Signaling, Rennes 1 University, Rennes, France

Correspondence to: Fabien Robin, MD, MSc. Department of Hepatobiliary and Digestive Surgery, University Hospital, Rennes 1 University, Rennes, France. Email:

Comment on: van Rijn R, Schurink IJ, de Vries Y, et al. Hypothermic machine perfusion in liver transplantation—a randomized trial. N Engl J Med 2021;384:1391-401.

Submitted Apr 08, 2021. Accepted for publication Apr 19, 2021.

doi: 10.21037/hbsn-21-144

We read with great interest the article by van Rijn et al. published in March 2021, in The New England Journal of Medicine (1). In this multicenter, randomized controlled trial, the authors investigated the efficacy of dual hypothermic oxygenated perfusion (D-HOPE) versus static cold storage (SCS) in grafts from donors after cardiac death (DCD) to decrease the rate of non-anastomotic biliary stenosis (NAS) within the first 6 post-transplant months. One hundred and seventy-eight patients were included and the outcome of 78 D-HOPE-grafts were compared with 78 SCS-grafts. The rates of NAS were 6% and 18% in the D-HOPE group and the SCS group, respectively (HR =0.36; 95% CI: 0.14–0.94; P=0.03). The incidence of reperfusion syndrome and early allograft dysfunction (EAD) defined according to the Olthoff criteria, were secondary endpoints and were significantly lower in the D-HOPE group. The authors should be commended for conducting the first randomized controlled trial evaluating D-HOPE and we found it relevant that the authors directly investigated DCD grafts since they represent an increasing source of donors.

There is no doubt that the oxygenated preservation technique will play an increasing role in preserving grafts retrieved from extended criteria donors. Based on this trial, D-HOPE has taken a place in the range of techniques for the preservation of grafts with extended criteria. Indeed, Guarrera et al. reported that oxygenated perfusion through the portal vein reduced hepatocyte suffering in expanded criteria grafts (2). More recently, Nasralla et al. (3) showed the benefit of normothermic oxygen perfusion (NOPE) in the preservation of liver grafts and in this study, a subgroup analysis showed the benefit of NOPE in preserving ECD grafts.

However, in this outstanding publication, two ideas should be discussed regarding the primary endpoint and the procurement procedure in DCD. To our knowledge, this is the first study to define NAS with precision. Indeed, post-transplant biliary complications can have multiple causes but NAS is directly linked to prolonged ischemia of the bile ducts and should not be related to anastomotic stenosis due to technical reasons or hepatic artery stenosis or thrombosis. In this trial, the need to meet five clinical, radiological and biological criteria avoids the risk of overestimating the rate of NAS. We found, however, that the rate of NAS that enabled calculation of the H1 hypothesis (29% in CSC livers) was overestimated. As a matter of fact, the final rate of NAS in the SCS arm was only 18%.

In France, the rate of NAS in DCD is only 6% (4)! This low percentage is related to the conditions in which the DCD are managed. As shown in Figure 1, 5 minutes after asystole, the femoral artery and vein are cannulated and extracorporeal membrane oxygenation (ECMO) is initiated. This in situ normothermic regional perfusion (NRP) restores blood supply to the abdominal organs after death using extracorporeal circulation for a limited period before organ recovery. More specifically, it participates in restoring physiologic oxygenation of the biliary tree. Using this technique, Watson et al. (5) recently reported the results of a series 43 livers retrieved from DCD + NRP. None of the recovered livers developed cholangiopathy compared with a 27% total incidence of cholangiopathy in non-NRP livers (P<0.0001). Moreover, patient and graft survival was improved in the DCD-NRP group. In 2020, Muller et al. (4) performed an international multicenter retrospective study comparing the outcome of livers retrieved from DCD without NRP and preserved with HOPE (portal only, DCD + HOPE) with livers retrieved from DCD + NRP + SCS. The rate of NAS in the DCD + HOPE group was 8.6%, i.e., close to the 6% reported by van Rijn et al. whereas it was 4% in the DCD + NRP + SCS group (1).

Figure 1 Diagram of the procedural steps in the procurement of DCD donors. The left side shows the procedure performed in the trial and the right side shows the procedure performed in France. DCD, donors after cardiac death; NRP, normothermic regional perfusion.

This trial is a great contribution to countries that apply the super rapid procurement technique to DCD. Indeed, this dynamic preservation method is expected to close the gap with transplantation from brain-dead donors and increase the pool of functional grafts. However, even if the authors rightly point out the simplicity and safety of D-HOPE as an argument for its widespread use, we believe that HOPE or even NOPE could provide equivalent results.

In conclusion, this work is a major milestone in the quest for optimal liver graft preservation. Given that it is a multicenter study of good methodological quality, its results should be considered reliable. Several other trials are expected to be completed in the near future to reinforce the value of organ perfusion in transplantation. A next step could be a prospective randomized three-arm study comparing HOPE, D-HOPE and NOPE as methods to reduce the risks of NAS in DCD.


Funding: None.


Provenance and Peer Review: This article was commissioned by the editorial office, Hepatobiliary Surgery and Nutrition. The article did not undergo external peer review.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See:


  1. van Rijn R, Schurink IJ, de Vries Y, et al. Hypothermic machine perfusion in liver transplantation—a randomized trial. N Engl J Med 2021;384:1391-401. [Crossref] [PubMed]
  2. Guarrera JV, Henry SD, Samstein B, et al. Hypothermic machine preservation in human liver transplantation: the first clinical series. Am J Transplant 2010;10:372-81. [Crossref] [PubMed]
  3. Nasralla D, Coussios CC, Mergental H, et al. A randomized trial of normothermic preservation in liver transplantation. Nature 2018;557:50-6. [Crossref] [PubMed]
  4. Muller X, Mohkam K, Mueller M, et al. Hypothermic oxygenated perfusion versus normothermic regional perfusion in liver transplantation from controlled donation after circulatory death: first international comparative study. Ann Surg 2020;272:751-8. [Crossref] [PubMed]
  5. Watson CJE, Hunt F, Messer S, et al. In situ normothermic perfusion of livers in controlled circulatory death donation may prevent ischemic cholangiopathy and improve graft survival. Am J Transplant 2019;19:1745-58. [Crossref] [PubMed]
Cite this article as: Robin F, Jeddou H. Comment on “Hypothermic machine perfusion in liver transplantation—a randomized trial”. Hepatobiliary Surg Nutr 2021;10(3):364-366. doi: 10.21037/hbsn-21-144